Packaging as a Quality Attribute: Why Container–Closure Systems Are No Longer an Afterthought

Key Takeaways:

• Packaging now shapes product quality, influencing stability, safety, and regulatory risk—not just containment.

• Container–closure integrity extends beyond sterility, affecting oxygen exposure, moisture control, and vacuum retention.

• CCI is increasingly treated as a CQA that must be designed into the product, not verified at the end.

• Regulatory frameworks reinforce life cycle accountability, elevating packaging into the core pharmaceutical quality system.

• Extractables and leachables force earlier decisions, tying packaging materials directly to patient safety and product risk.

For much of the pharmaceutical industry’s history, packaging was treated as a largely passive element of drug development. The role of packaging was straightforward: contain the product, protect it from the external environment, and ensure it could be transported and stored without visible degradation. Decisions around containers and closures were often finalized late in development and viewed as an operational necessity rather than a strategic variable. As long as the drug remained stable and sterile within the selected vial, syringe, or bottle, packaging was considered to have done its job.

That assumption has steadily eroded as injectable therapies and combination products have grown more complex. Modern biologics, highly potent compounds, and advanced delivery systems place far greater demands on their surrounding materials. Drug products may be sensitive to trace extractables, adsorption to container surfaces, mechanical stress during handling, or subtle changes in oxygen and moisture exposure. In these contexts, packaging no longer simply houses the drug; it interacts with it. The container–closure system can influence stability profiles, dosing accuracy, particulate formation, and even clinical performance.

At the same time, regulatory expectations have evolved. Authorities increasingly view container–closure systems as integral to product quality and patient safety, not as peripheral components. Failures linked to leachables, breakage, or inconsistent performance can trigger significant regulatory scrutiny, delayed approvals, or post-market actions. As a result, packaging choices now carry implications for development timelines, manufacturing risk, and lifecycle management.

This shift marks a broader change in how packaging is understood across the industry. Container–closure systems have moved from passive safeguards to active contributors to product behavior and regulatory risk. Recognizing and managing that reality early in development has become essential for sponsors seeking predictable outcomes in today’s increasingly complex pharmaceutical landscape.

For decades, container–closure integrity (CCI) has been understood primarily through the lens of sterility assurance. The core objective was straightforward: prevent microbial ingress over the product’s shelf life and through its intended use. CCI testing strategies, acceptance criteria, and regulatory discussions were therefore largely anchored to maintaining a sterile barrier, particularly for parenteral products.

While sterility remains foundational, this narrow framing no longer captures the full scope of what container–closure systems are now expected to deliver. As injectable products have become more sensitive and structurally complex, the function of CCI has expanded beyond blocking microorganisms to controlling the microenvironment within the package itself. Even in the absence of microbial ingress, subtle failures in container performance can compromise product quality in ways that are not immediately visible but are clinically and commercially significant.

One important dimension of this expanded role is protection from oxygen and other reactive gases. Many biologics and small molecule injectables are susceptible to oxidative degradation at very low exposure levels. Inadequate barrier performance, microleaks, or gradual permeability through elastomeric components can allow oxygen ingress that accelerates chemical degradation long before sterility is compromised. In these cases, the container–closure system becomes a determinant of chemical stability rather than a neutral enclosure.

Water vapor control represents a related challenge, particularly for moisture-sensitive formulations and lyophilized products. Even trace amounts of moisture ingress can alter residual moisture levels, destabilize the solid-state structure of the drug, or promote aggregation and degradation. Maintaining a controlled internal environment over time requires consistent barrier performance across all components of the container–closure system, including vials, stoppers, seals, and interfaces between them.

For lyophilized products, CCI performance is also directly tied to vacuum maintenance. Loss of vacuum can indicate compromised closure integrity and may correlate with increased moisture ingress or changes in reconstitution behavior. In these products, the container–closure system plays an active role in preserving the physical state of the dosage form, not simply its sterility.

Taken together, these factors illustrate a broader shift in how CCI must be evaluated and managed. Packaging performance now influences chemical stability, physical integrity, and ultimately shelf life and efficacy, even in the absence of microbial contamination. As a result, CCI has evolved from a single-purpose sterility safeguard into a multidimensional quality attribute that sits at the intersection of formulation science, materials engineering, and regulatory risk management.

As the role of packaging has expanded, container–closure integrity has undergone a parallel conceptual shift. Once treated as a confirmatory test applied late in development, CCI is increasingly understood as a critical quality attribute (CQA) that must be designed, controlled, and maintained throughout the product life cycle. This reframing reflects a growing recognition that CCI is not simply a pass/fail checkpoint but a fundamental determinant of product quality, stability, and patient safety.

Viewing CCI as a CQA places it alongside attributes such as potency, purity, and stability rather than beneath them. In this context, integrity is not an outcome that can be reliably verified at the end of development if upstream decisions have already constrained performance. Instead, CCI emerges from a chain of interdependent choices spanning container materials, closure components, fill–finish processes, and handling conditions. Weakness at any point in that chain can undermine integrity long after the product has left the manufacturing site.

This life cycle perspective reshapes how CCI is managed. Design robustness becomes the first line of defense, encompassing container geometry, material selection, and compatibility with the drug product. Assembly and sealing processes then translate that design into a physical system, where variables such as stopper placement, crimp force, and sealing consistency directly influence integrity. Once packaged, the product must withstand storage and transport stresses — including temperature excursions, pressure changes, and mechanical shock — without compromising the container–closure interface. Finally, performance at the end of shelf life must still meet integrity expectations, ensuring that protection against environmental ingress is maintained until the point of use.

Taken together, these stages underscore why CCI cannot be relegated to a single test or a late-stage validation exercise. A “test at the end” mindset assumes that integrity can be inspected into existence, rather than engineered and preserved. In contrast, a “build quality in” approach treats CCI as an attribute that is proactively designed, continuously controlled, and verified with methods appropriate to each phase of the product life cycle.

This shift represents the conceptual core of modern packaging strategy. When CCI is treated as a true CQA, packaging decisions move upstream, cross-functional alignment improves, and risks that once surfaced late — often during stability studies or regulatory review — can be anticipated and mitigated earlier. In an environment where development timelines are compressed and tolerance for failure is low, integrating CCI into the foundation of product quality is no longer optional; it is essential.

Regulatory expectations around packaging have not shifted through a single, abrupt rule change. Instead, they have evolved steadily, sending increasingly clear signals that container–closure systems are a regulated, inspectable element of pharmaceutical quality systems rather than a peripheral technical detail. This gradual elevation is evident across both U.S. and European regulatory frameworks, where packaging integrity has been woven more tightly into broader concepts of product quality and risk management over time.

In the United States, this evolution can be traced back decades. As early as 1999, regulatory guidance made clear that packaging information was not merely supportive documentation, but an expected component of regulatory submissions for sterile products.¹ This framing implicitly acknowledged that container–closure systems contribute directly to product performance and patient safety and therefore warrant formal evaluation and justification alongside formulation and manufacturing processes. While the language at the time may have emphasized sterility, it established the precedent that packaging decisions fall squarely within the scope of regulatory review.

In Europe, this perspective has continued to mature through updates to good manufacturing practice (GMP) requirements, most notably in Annex 1. Rather than isolating sterility assurance as a single objective, Annex 1 reinforces a holistic approach grounded in Quality Risk Management applied throughout the product life cycle.² Contamination control is framed not as a discrete test or validation exercise, but as a system that integrates facility design, process controls, materials, and packaging performance into a unified strategy.

Within this systems-based view, CCI is inseparable from contamination control and product protection. Packaging components, assembly processes, and long-term performance are all subject to the same risk-based scrutiny as upstream manufacturing steps. This does not represent a sudden tightening of expectations but rather a clarification of how existing principles should be applied consistently across all elements that influence product quality.

The cumulative effect of these regulatory signals is significant. Packaging is no longer treated as an operational afterthought that can be addressed late in development or delegated entirely to downstream teams. Instead, it is recognized as a controlled element of the pharmaceutical quality system that can be examined during inspections, questioned during review, and linked directly to stability outcomes and patient risk.

By emphasizing integration rather than exception, regulators have effectively elevated packaging decisions without rewriting the rules. For sponsors, the implication is clear: container–closure systems must be developed, justified, and controlled with the same rigor as any other critical aspect of the drug product, because regulators increasingly view them that way.

Few issues have done more to elevate packaging from a downstream consideration to an early strategic decision than extractables and leachables (E&L). Once treated as a largely confirmatory exercise conducted late in development, E&L assessment now serves as a forcing function that directly links packaging materials to patient safety and product quality.

At its core, E&L risk reflects the reality that packaging materials are not inert. Polymers, elastomers, coatings, and adhesives can release chemical species into the drug product under certain conditions. These species may pose toxicological risks to patients or interact with the formulation in ways that compromise stability, potency, or efficacy. As regulatory expectations have matured, the presence of leachables is no longer viewed solely as a packaging issue, but as a potential clinical and safety concern that must be understood, justified, and controlled.³

This shift has important implications for how risk is assessed. Modern E&L strategies are explicitly risk-based, requiring an understanding of material composition, processing conditions, and the full range of product contact scenarios over the intended shelf life. That assessment cannot be meaningfully performed if packaging materials and container–closure systems are selected late, after formulation and fill–finish decisions are already locked in. By that point, the ability to mitigate risk through design changes may be limited, costly, or incompatible with development timelines.

As a result, packaging choices now influence more than mechanical performance or sterility assurance. They shape toxicological evaluations, inform clinical risk profiles, and may affect regulatory confidence in the overall control strategy. A material with an unfavorable extractables profile, or a system with poorly characterized interactions, can introduce uncertainty that ripples through nonclinical assessments, stability programs, and ultimately clinical development.

In this context, E&L considerations make deferring packaging decisions increasingly untenable. Early material selection and system design are no longer optional optimizations; they are prerequisites for building a defensible safety and quality narrative. By forcing sponsors to confront the chemical reality of packaging components early, E&L risk assessment reinforces a broader truth of modern drug development: container–closure systems actively participate in defining product risk, and must be treated accordingly from the outset.

Taken together, the expanded role of container–closure integrity, the elevation of packaging to a CQA, and the growing influence of E&L all point to the same conclusion: traditional, after-the-fact approaches to packaging are no longer sufficient. The risks associated with container–closure systems do not emerge at a single moment that can be addressed through end-stage testing alone. They accumulate across the life cycle, shaped by early design choices and reinforced — or undermined — by subsequent execution.

Life cycle risk is central to this shift. A container–closure system that performs adequately at release may still fail to protect product quality over time, under transport stress, or near the end of shelf life. Similarly, E&L risks cannot be fully understood if material selection and system design are treated as fixed constraints rather than variables to be actively managed. Stability outcomes, too, increasingly reflect subtle interactions between formulation and packaging that cannot be “tested away” once development is complete.

These converging demands expose the limitations of a mindset focused primarily on demonstration. Proving that a finished product meets integrity requirements at a single point in time does not guarantee that integrity was intentionally built into the system. Without explicit design intent — grounded in material science, process understanding, and risk-based decision-making — testing becomes a retrospective exercise, identifying problems only after options for mitigation have narrowed.

This reality has driven a broader reassessment of how packaging quality is achieved. The question is no longer whether integrity can be demonstrated but whether it has been deliberately engineered and preserved across the product lifecycle. That distinction matters, because regulators increasingly expect evidence of control, not just confirmation of outcome.

With after-the-fact thinking no longer holding, the focus shifts toward operationalizing this new expectation. The challenge becomes translating conceptual recognition of packaging as a quality driver into practical strategies that embed integrity, stability, and safety into development workflows from the start. That transition — from awareness to execution — sets the stage for the next part of the discussion, where the emphasis moves from why packaging decisions matter to how modern organizations are responding in practice.

The evolution of packaging from a passive safeguard to an engineered quality decision reflects a broader transformation in how pharmaceutical products are developed, evaluated, and regulated. Container–closure systems no longer sit at the periphery of development strategy. They actively shape stability, safety, and regulatory risk, influencing outcomes across the product life cycle in ways that cannot be isolated or deferred.

This shift challenges long-standing assumptions. Sterility alone is no longer a sufficient proxy for performance. Demonstration at the end of development is no longer a reliable substitute for intentional design. Instead, packaging decisions now demand the same level of scientific rigor, risk-based thinking, and lifecycle awareness applied to formulation and manufacturing processes. When CCI, material interactions, and long-term performance are treated as engineered attributes rather than downstream checks, packaging becomes a lever for predictability rather than a source of late-stage uncertainty.

Recognizing packaging as an engineered quality decision is not simply a conceptual exercise; it is a practical necessity in an environment defined by complex injectables, compressed timelines, and heightened regulatory scrutiny. The implications are clear, but the path forward requires more than awareness. It requires new ways of working — approaches that embed quality intent into packaging choices from the outset and align materials, processes, and testing strategies around that goal.

1. Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. U.S. Department of Health and Human Services. May 1999.

2. The Rules Governing Medicinal Products in the European Union. Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use: Annex 1. European Commission. 22 Aug. 2022.

3. USP <1207> Package Integrity Evaluation — Sterile Products. U.S. Pharmacopeia. 1 Aug. 2016.